PSFG
CYTK icon

Park Square Financial Group’s Cytokinetics CYTK Stock Holding History

Park Square Financial Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-265
Closed -$8.76K – 417
2025
Q2 		$8.76K Hold
265
– – 0.01% 624
2025
Q1 		$10.7K Hold
265
– – 0.01% 584
2024
Q4 		$12.5K Buy
+265
New +$13.8K 0.01% 542

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Park Square Financial Group's CYTK Position: Q3 2025 in Review

Park Square Financial Group sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 265 shares — an estimated $8.76K sold.

Park Square Financial Group first reported a position in CYTK in Q4 2024 and held it in 3 quarters. The position peaked at $12.5K in Q4 2024. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • Park Square Financial Group reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 265 Cytokinetics shares in Q3 2025, an estimated $8.76K.
  • Park Square Financial Group first reported a position in Cytokinetics in Q4 2024 and held it in 3 quarters.
  • Park Square Financial Group's Cytokinetics position peaked at $12.5K in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.